ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last541 to 560 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
No PN Use (Project B) vs PN Use (Project B): Need for Surgical Procedures (Project B)69 of 8,146

147 of 8,146

-1.0 points

-1.3 to -0.6

16,292NCT03767634

Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates

No PN Use (Project B) vs PN Use (Project B): Late Onset Sepsis (Project B)59 of 8,146

179 of 8,146

-1.5 points

-1.9 to -1.1

16,292NCT03767634

Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates

No PN Use (Project B) vs PN Use (Project B): Retinopathy of Prematurity (Project B)272 of 8,146

297 of 8,146

-0.3 points

-0.9 to 0.3

16,292NCT03767634

Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates

No PN Use (Project B) vs PN Use (Project B): Seizures (Project B)81 of 8,146

114 of 8,146

-0.4 points

-0.7 to -0.1

16,292NCT03767634

Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates

No PN Use (Project B) vs PN Use (Project B): Brain Injury on Imaging (Project B)48 of 8,146

73 of 8,146

-0.3 points

-0.6 to -0.0

16,292NCT03767634

Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates

No PN Use (Project B) vs PN Use (Project B): Bronchopulmonary Dysplasia (Project B)302 of 8,146

619 of 8,146

-3.9 points

-4.6 to -3.2

16,292NCT03767634

Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates

No PN Use (Project B) vs PN Use (Project B): Survival to Discharge Home (Project B)7,987 of 8,146

8,057 of 8,146

-0.9 points

-1.2 to -0.5

16,292NCT03767634

Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates

High Touch vs Usual Care: Number of Staff Who Received SARS-CoV-2 Vaccine4,098 of 7,555

4,643 of 8,716

1.0 points

-0.6 to 2.5

16,271NCT04732819

Improving COVID-19 Vaccine Uptake in Nursing Homes

ARCT-154 vs Placebo: Number of Participants With a First Occurrence of COVID-19223 of 8,056

496 of 8,044

-3.4 points

-4.0 to -2.8

16,100NCT05012943

The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)

Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI)304 of 7,980

349 of 7,988

-0.6 points

-1.2 to 0.1

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With All-cause Mortality224 of 7,980

253 of 7,988

-0.4 points

-0.9 to 0.2

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With Myocardial Infarction248 of 7,980

250 of 7,988

-0.0 points

-0.6 to 0.5

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Myocardial Revascularisation739 of 7,980

793 of 7,988

-0.7 points

-1.6 to 0.2

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With New Q-wave Myocardial Infarction83 of 7,980

103 of 7,988

-0.2 points

-0.6 to 0.1

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Bleeding Academic Research Consortium (BARC) 3 or 5 Bleeding163 of 7,980

169 of 7,988

-0.1 points

-0.5 to 0.4

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Definite Stent Thrombosis64 of 7,980

64 of 7,988

0.0 points

-0.3 to 0.3

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Experimental Treatment Strategy vs Reference Treatment Strategy: deaths from any cause224 of 7,980

253 of 7,988

-0.4 points

-0.9 to 0.2

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Composite of All-cause Mortality, Stroke, or New Q-wave Myocardial Infarction362 of 7,980

416 of 7,988

-0.7 points

-1.3 to -0.0

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Stroke80 of 7,980

82 of 7,988

-0.0 points

-0.3 to 0.3

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Experimental Treatment Strategy vs Reference Treatment Strategy: serious adverse events1,459 of 7,980

1,543 of 7,988

-1.0 points

-2.2 to 0.2

15,968NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=28

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03767634-1aa571bd",
        "title": "No PN Use (Project B) vs PN Use (Project B): Need for Surgical Procedures (Project B)",
        "summary": "69 of 8146 against 147 of 8146; risk difference -1.0 points, 95% interval -1.3 to -0.6; NCT03767634, Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates",
        "record": "/library/comparisons/NCT03767634-1aa571bd",
        "nct_id": "NCT03767634",
        "kind": "outcome",
        "participants": 16292,
        "risk_difference": {
          "value": -0.009575251657255094,
          "lower": -0.01316839213988061,
          "upper": -0.006092039863011531
        },
        "group_1": "69 of 8,146",
        "group_2": "147 of 8,146",
        "difference": "-1.0 points",
        "interval": "-1.3 to -0.6",
        "trial_title": "Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates"
      },
      {
        "id": "NCT03767634-435f8cad",
        "title": "No PN Use (Project B) vs PN Use (Project B): Late Onset Sepsis (Project B)",
        "summary": "59 of 8146 against 179 of 8146; risk difference -1.5 points, 95% interval -1.9 to -1.1; NCT03767634, Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates",
        "record": "/library/comparisons/NCT03767634-435f8cad",
        "nct_id": "NCT03767634",
        "kind": "outcome",
        "participants": 16292,
        "risk_difference": {
          "value": -0.014731156395777066,
          "lower": -0.018513279436599004,
          "upper": -0.011104497567864236
        },
        "group_1": "59 of 8,146",
        "group_2": "179 of 8,146",
        "difference": "-1.5 points",
        "interval": "-1.9 to -1.1",
        "trial_title": "Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=29",
  "request_id": "-aTKN9cxiPXwnwBe"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?